Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘GlaxoSmithKline’

GlaxoSmithKline aims for the whole consumer-health shebang with $10.3B Novartis JV buyout

Next March, GlaxoSmithKline will have the option to buy out Novartis’ stake in the pair’s industry-leading consumer health JV. And it may already be getting prepared. The British drugmaker is getting its ducks in a row for an £8 billion ($10.3 billion) offer for its partner’s 36.5% share, top shareholders told The Sunday Times.

Bron: FiercePharma Meer lezen »

GSK applies for EU approval for shingles vaccine

After filing for FDA approval in October, GlaxoSmithKline has now applied for approval from the European Commission (EC) for its shingles (herpes zoster) treatment Shingrix.

Bron: Meer lezen »

GSK reaches endgame of race to develop anaemia drug

GlaxoSmithKline has announced that they will begin Phase 3 development of their anaemia drug, daprodustat. The drug is an oral treatment for anaemia associated with chronic kidney disease and will be tested through two trials, with a combined total of 7,500 patients.

Bron: Meer lezen »

GSK/J&J release how their drug measures up against Humira

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options for adults suffering from active rheumatoid arthritis, in comparison with market leader Humira.

Bron: Meer lezen »

GSK emerges top of the pile for improving access to medicine

GlaxoSmithKline, the British drugmaker, has topped the overall ranking of the Access to Medicine Index, which ranks 20 top pharmaceutical companies by the availability of the firm’s drug portfolio. It is the fifth time that GSK have been ranked in the lead position in the Index, they also topped the list for considering affordability when […]

Bron: Meer lezen »

GSK launches patent infringement action against Pfizer

GlaxoSmithKline has filed a patent infringement lawsuit against rival Pfizer over the alleged copying of its popular meningococcal group B vaccine Bexsero.  

Bron: Meer lezen »

GSK applies for FDA approval for shingles vaccine

GlaxoSmithKlien, the UK’s biggest drugmaker, is seeking approval from the FDA for a shingles (herpes zoster) vaccine. The vaccine would be for those of 50 years and above to prevent the emergence of shingles later in life. The vaccine will be known as Shingrix, should it be released onto the market.  

Bron: Meer lezen »

GSK appoints Emma Walmsley as first female CEO

GlaxoSmithKline, the UK’s biggest drugs company, has appointed Emma Walmsley as its new CEO. Walmsley will step into the vacancy left by current CEO Sir Andrew Witty who will step down in March 2017.  

Bron: Meer lezen »

GSK’s shingles vaccine tops MSD rival in Phase III testing

GlaxoSmithKline’s shingles vaccine Shingrix has topped rival MSD treatment Zostavax as it is shown to remain effective in elderly patients after four years, according to a recent Phase III study published in the New England Journal of Medicine.

Bron: Meer lezen »

GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in Europe in an attempt to compete with Roche’s $1.5 billion Actemra.

Bron: Meer lezen »

« Oudere artikelen |